Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Summary

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

Timeline

Start

2014-10-31

Primary completion

2015-04-30

Completion

2015-06-30

Outcome

Missed primary endpoint

paper Treatment with selexipag did not reduce the number of RP attacks compared with placebo. PMID 29193819 ↗

Publications

• Denton CP, Hachulla E, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.

Drugs

Indications